drugset / Trial / NCT00712712

Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer

NCT00712712

Phase 2 Completed 78 enrolled Institut Bergonié
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Morphine may reduce pain in patients who have undergone radiofrequency ablation to remove bone metastases. PURPOSE: This phase II trial is studying how well morphine works after radiofrequency ablation of painful bone metastases in patients with cancer.

Timeline

Start
2007-12-24
Primary completion
2016-02-11
Completion
2016-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified
Background Acetaminophen Small molecule 4 g Intravenous